ALT Altimmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALT

Price (delayed)

$4.82

Market cap

$237.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$126.39M

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), ...

Highlights
Altimmune's EPS has increased by 23% YoY and by 4.7% QoQ
Altimmune's net income has increased by 13% YoY and by 2.6% QoQ
ALT's quick ratio is down by 16% QoQ but it is up by 3.9% YoY
The gross profit has plunged by 102% from the previous quarter and by 102% YoY
ALT's revenue has dropped by 102% since the previous quarter and by 102% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.altimmune.com
Peers: OCUP

Key stats

What are the main financial stats of ALT
Market
Shares outstanding
49.28M
Market cap
$237.52M
Enterprise value
$126.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$68,000
EBIT
-$84.9M
EBITDA
-$85.11M
Free cash flow
-$62.71M
Per share
EPS
-$1.81
Free cash flow per share
-$1.34
Book value per share
$3.77
Revenue per share
$0
TBVPS
$4.14
Balance sheet
Total assets
$206.93M
Total liabilities
$21.64M
Debt
$0
Equity
$185.29M
Working capital
$175.76M
Liquidity
Debt to equity
0
Current ratio
11.31
Quick ratio
10.85
Net debt/EBITDA
1.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-40%
Return on equity
-44%
Return on invested capital
-191%
Return on capital employed
-44.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALT stock price

How has the Altimmune stock price performed over time
Intraday
11.57%
1 week
-55.86%
1 month
-59.26%
1 year
-24.57%
YTD
-70.7%
QTD
-70.7%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
-$68,000
Gross profit
-$68,000
Operating income
-$87.74M
Net income
-$84.71M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 102% from the previous quarter and by 102% YoY
ALT's revenue has dropped by 102% since the previous quarter and by 102% year-on-year
Altimmune's net income has increased by 13% YoY and by 2.6% QoQ
Altimmune's operating income has increased by 9% YoY

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
1.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Altimmune's EPS has increased by 23% YoY and by 4.7% QoQ
The P/B is 56% lower than the last 4 quarters average of 2.9 and 15% lower than the 5-year quarterly average of 1.5
The equity has declined by 10% since the previous quarter and by 7% year-on-year
ALT's revenue has dropped by 102% since the previous quarter and by 102% year-on-year

Efficiency

How efficient is Altimmune business performance
The company's return on invested capital rose by 40% QoQ and by 11% YoY

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Altimmune financials performed over time
Altimmune's current ratio has decreased by 16% from the previous quarter
ALT's quick ratio is down by 16% QoQ but it is up by 3.9% YoY
The debt is 100% smaller than the equity
The equity has declined by 10% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.